Health Economics›Polycythemia vera›First-line therapy

First-line therapy

Polycythemia vera · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Hydroxyurea monotherapy Variant #01	—	R 278	28d	—	243.6 mo	—	—	—
Aspirin monotherapy Variant #01	—	R 26	28d	—	—	—	—	—
Ropeginterferon alfa-2b monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145

4 of 4 regimens shown